Skip to main content

Table 1 Baseline characteristics and surgical procedures

From: Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial

  Control (n = 15) Low Dose (n = 15) High Dose (n = 15) Total (n = 45)
Age (years) (mean, SD) 55.5 (15.3) 57.5 (13.2) 53.8 (9.9) 55.6 (12.8)
Surgery Type (N, %)
 Lumpectomy 10 (66.7) 9 (60.0) 10 (66.7) 29 (64.4)
 Mastectomy 5 (33.3) 6 (37.5) 5 (33.3) 16 (35.5)
Diagnosis (N, %)
 IDC 13 (86.7) 13 (86.7) 11 (73.3) 37 (82.2)
 ILC 1 (6.7) 2 (13.3) 4 (26.7) 7 (15.6)
 IMC 1 (6.7) 0 (0.0) 0 (0.0) 1 (6.7)
Primary Tumour Size (cm) (mean, SD) 3.1 (1.2) 2.7 (0.9) 3.3 (2.2) 3.0 (1.5)
Grade (N, %)
 1 1 (6.7) 1 (6.7) 1 (6.7) 3 (6.7)
 2 4 (26.6) 6 (40.0) 5 (33.3) 15 (33.3)
 3 10 (66.7) 8 (53.3) 9 (60.0) 27 (60.0)
Mitotic Score (N, %)
 1 4 (26.7) 5 (33.3) 5 (33.3) 14 (31.1)
 2 3 (20.0) 3 (20.0) 4 (26.7) 10 (22.2)
 3 8 (53.3) 7 (46.7) 6 (37.5) 21 (46.7)
ER Status (N, %)
 Positive 12 (80.0) 12 (80.0) 11 (73.3) 35 (77.8)
 Negative 3 (20.0) 3 (20.0) 4 (26.7) 10 (22.2)
PR Status (N, %)
 Positive 12 (80.0) 10 (66.7) 10 (66.7) 32 (71.1)
 Negative 3 (20.0) 5 (33.3) 5 (33.3) 13 (28.9)
Her2 Status (N, %)
 Positive 1 (6.7) 4 (26.7) 2 (13.3) 7 (15.6)
 Negative 14 (93.3) 11 (73.3) 13 (86.7) 38 (84.4)
DCIS Present (N, %)
 Yes 12 (80.0) 10 (66.7) 9 (60.0) 31 (68.9)
 No 3 (20.0) 5 (33.3) 6 (37.5) 14 (31.1)
Margin Status (N, %)
 Positive (Invasive) 1 (6.7) 1 (6.7) 4 (26.7) 6 (13.3)
 Negative (Invasive) 14 (93.3) 14 (93.3) 11 (73.3) 39 (86.7)
 Positive (DCIS) 1 (6.7) 0 (0.0) 1 (6.7) 2 (4.4)
 Negative (DCIS) 14 (93.3) 15 (100) 14 (93.3) 43 (95.6)
Revised Margins at Index Surgery (N, %)a
 Yes 3 (20.0) 3 (20.0) 4 (26.7) 10 (22.2)
 No 12 (80.0) 12 (80.0) 11 (73.3) 35 (77.8)
Re-excision (N, %)
 Yes 2 (13.3) 1 (6.7) 3 (20.0) 6 (13.3)
 No 13 (86.7) 14 (93.3) 12 (80.0) 39 (86.7)
  1. SD standard deviation, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mammary carcinoma, ER estrogen receptor, PR progesterone receptor, HER2 Human epidermal growth factor receptor 2, DCIS ductal carcinoma in situ
  2. amargin revision not guided by fluorescence imaging